Cancer research

Cancer research

Pembrolizumab Plus Enzalutamide Combo Fails to Improve Efficacy in Metastatic Prostate Cancer Patients

Researchers at Oregon Health & Science University (OHSU) have conducted a Phase III clinical trial to evaluate the efficacy of pembrolizumab added to enzalutamide in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). The study, KEYNOTE-641, involved 615 participants and showed that the combination of pembrolizumab and enzalutamide did not